Literature DB >> 30661935

Feasibility Outcomes of a Pilot Randomized Clinical Trial to Increase Cruciferous and Green Leafy Vegetable Intake in Posttreatment Head and Neck Cancer Survivors.

Sylvia L Crowder, Andrew D Frugé, Katherine G Douglas, Yi Tang Chen, Laura Moody, Ashley Delk-Licata, John W Erdman, Molly Black, William R Carroll, Sharon A Spencer, Julie L Locher, Wendy Demark-Wahnefried, Laura Q Rogers, Anna E Arthur.   

Abstract

BACKGROUND: Higher intakes of cruciferous vegetables (CVs) and green leafy vegetables (GLVs) in observational studies are associated with improvements in survival and cancer-related biomarkers in patients diagnosed with head and neck cancer (HNC). These results have yet to be corroborated in a randomized clinical trial (RCT).
OBJECTIVE: Determine the feasibility of implementing a 12-week RCT to increase CV and GLV intake in posttreatment HNC survivors. DESIGN AND PARTICIPANTS: This was a two-arm RCT conducted among 24 posttreatment HNC survivors. Survivors were recruited from a southeastern, National Cancer Institute-designated Comprehensive Cancer Center between January 2015 and September 2016. INTERVENTION: There were two groups: (1) an experimental group (n=12) receiving weekly 15- to 30-minute telephone dietary counseling from a registered dietitian nutritionist stressing 2.5 cups per week CVs and 3.5 cups per week GLVs, and (2) an attention control group (n=12) receiving weekly 15- to 30-minute telephone dietary counseling from a registered dietitian nutritionist focusing on general healthy eating for cancer survivors. Participants completed a baseline survey, three 24-hour dietary recalls, phlebotomy, and anthropometric measures prior to randomization and at the end of the 12-week study period. The experimental group also completed weekly vegetable record recalls. MAIN OUTCOME MEASURES: Primary outcomes included feasibility, recruitment, retention, adherence, and safety. Secondary outcomes included inflammatory markers and carotenoids. STATISTICAL ANALYSES PERFORMED: Descriptive statistics were generated for demographic, epidemiological, and clinical variables as well as the primary feasibility outcomes. Between- and within-group comparisons of mean serum cytokine and carotenoid levels were performed using appropriate statistical tests depending on their respective distributions for the purpose of generating preliminary effect sizes.
RESULTS: Overall, 350 incident HNC cases were screened for eligibility, and 98 were eligible for study participation. Reasons for ineligibility and exclusion included deceased (n=93); wrong or inactive telephone numbers, or unable to be reached, or lost to follow-up (n=93); not meeting inclusion criteria (n=39); and too ill to participate (n=27). Of the 98 eligible HNC cases, 24 agreed to participate, for an enrollment rate of 25%. The most common reason for nonparticipation was distance (n=48), as participants were asked to report for two on-site assignments. The retention rate was 96%. Mean intervention adherence rates for weekly goals were 67% CV, 74% GLV, and 71% overall. Completion rate of weekly counseling calls was 90%. The experimental group reported an overall mean increase of 5.5 cups GLV and 3.5 cups CV per week from baseline intake, respectively. No significant between- or within-arm differences were observed for inflammatory markers or carotenoids.
CONCLUSION: A posttreatment intervention aimed at increasing CV and GLV intake in HNC survivors is feasible. A larger RCT is needed to assess the efficacy of this intervention on disease outcomes.
Copyright © 2019 Academy of Nutrition and Dietetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cruciferous vegetables; Dietary intervention; Green leafy vegetables; Head and neck cancer; Randomized clinical trial

Mesh:

Substances:

Year:  2019        PMID: 30661935      PMCID: PMC6433521          DOI: 10.1016/j.jand.2018.11.005

Source DB:  PubMed          Journal:  J Acad Nutr Diet        ISSN: 2212-2672            Impact factor:   4.910


  57 in total

1.  NIST micronutrients measurement quality assurance program: characterizing the measurement community's performance over time.

Authors:  D L Duewer; M C Kline; K E Sharpless; J B Thomas
Journal:  Anal Chem       Date:  2000-09-01       Impact factor: 6.986

2.  Serum carotenoids as biomarkers of fruit and vegetable consumption in the New York Women's Health Study.

Authors:  A L van Kappel; J P Steghens; A Zeleniuch-Jacquotte; V Chajès; P Toniolo; E Riboli
Journal:  Public Health Nutr       Date:  2001-06       Impact factor: 4.022

3.  NIST micronutrients measurement quality assurance program: characterizing individual participant measurement performance over time.

Authors:  D L Duewer; M C Kline; K E Sharpless; J B Thomas; M Stacewicz-Sapuntzakis; A L Sowell
Journal:  Anal Chem       Date:  2000-08-01       Impact factor: 6.986

4.  How does physician advice influence patient behavior? Evidence for a priming effect.

Authors:  M W Kreuter; S G Chheda; F C Bull
Journal:  Arch Fam Med       Date:  2000-05

5.  Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease.

Authors:  J K Smith; R Dykes; J E Douglas; G Krishnaswamy; S Berk
Journal:  JAMA       Date:  1999-05-12       Impact factor: 56.272

6.  Effectiveness of the US Department of Agriculture 5-step multiple-pass method in assessing food intake in obese and nonobese women.

Authors:  Joan M Conway; Linda A Ingwersen; Bryan T Vinyard; Alanna J Moshfegh
Journal:  Am J Clin Nutr       Date:  2003-05       Impact factor: 7.045

7.  Nutritional deterioration in cancer: the role of disease and diet.

Authors:  P Ravasco; I Monteiro-Grillo; P M Vidal; M E Camilo
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-12       Impact factor: 4.126

8.  Accuracy of dietary recall using the USDA five-step multiple-pass method in men: an observational validation study.

Authors:  Joan M Conway; Linda A Ingwersen; Alanna J Moshfegh
Journal:  J Am Diet Assoc       Date:  2004-04

9.  Clinical predictors of quality of life in patients with head and neck cancer.

Authors:  Jeffrey E Terrell; David L Ronis; Karen E Fowler; Carol R Bradford; Douglas B Chepeha; Mark E Prince; Theodoros N Teknos; Gregory T Wolf; Sonia A Duffy
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-04

10.  Does nutrition influence quality of life in cancer patients undergoing radiotherapy?

Authors:  Paula Ravasco; Isabel Monteiro-Grillo; Maria Ermelinda Camilo
Journal:  Radiother Oncol       Date:  2003-05       Impact factor: 6.280

View more
  4 in total

Review 1.  Dietary Carotenoids in Head and Neck Cancer-Molecular and Clinical Implications.

Authors:  Katarzyna Starska-Kowarska
Journal:  Nutrients       Date:  2022-01-26       Impact factor: 5.717

2.  Primary Outcomes of a Randomized Controlled Crossover Trial to Explore the Effects of a High Chlorophyll Dietary Intervention to Reduce Colon Cancer Risk in Adults: The Meat and Three Greens (M3G) Feasibility Trial.

Authors:  Andrew D Frugé; Kristen S Smith; Aaron J Riviere; Wendy Demark-Wahnefried; Anna E Arthur; William M Murrah; Casey D Morrow; Robert D Arnold; Kimberly Braxton-Lloyd
Journal:  Nutrients       Date:  2019-10-02       Impact factor: 5.717

3.  Head and neck cancer survivors' preferences for and evaluations of a post-treatment dietary intervention.

Authors:  Sylvia L Crowder; Katherine G Douglas; Andrew D Frugé; William R Carroll; Sharon A Spencer; Julie L Locher; Wendy Demark-Wahnefried; Laura Q Rogers; Anna E Arthur
Journal:  Nutr J       Date:  2019-09-10       Impact factor: 3.271

4.  Epigenetic stratification of head and neck cancer survivors reveals differences in lycopene levels, alcohol consumption, and methylation of immune regulatory genes.

Authors:  Laura Moody; Sylvia L Crowder; Andrew D Fruge; Julie L Locher; Wendy Demark-Wahnefried; Laura Q Rogers; Ashley Delk-Licata; William R Carroll; Sharon A Spencer; Molly Black; John W Erdman; Hong Chen; Yuan-Xiang Pan; Anna E Arthur
Journal:  Clin Epigenetics       Date:  2020-09-11       Impact factor: 6.551

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.